Tumours use various strategies to evade immune surveillance1,2.Immunotherapies targeting tumour immune evasion such as immune checkpoint blockade have shown considerable efficacy on multiple cancers3,4 but are ineffective for most patients due to primary or acquired resistance5-7.Recent studies showed that some epigenetic regulators suppress anti-tumour immunity2,8-12,suggesting that epigenetic therapies could boost anti-tumour immune responses and overcome resistance to current immunotherapies.Here we show that,in mouse melanoma models,depletion of KDM5B-an H3K4 demethylase that is critical for melanoma maintenance and drug resistance13-15-induces robust adaptive immune responses and enhances responses to immune checkpoint blockade.
展开▼
